Behaviour Analysis and Psychotropic Medication with Dr. Alison Cox, Ph.D., BCBA-D

episode

Previously titled “Episode 13: Behaviour Analysis and Psychotropic Medication with Dr. Alison Cox, Ph.D., BCBA-D” — renamed by the publisher on Aug 5, 2026

Behaviour Speak with Ben Reiman not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

recent transcribed audio

Finance and Budget Committee - Sep 15, 2026 1h 43m · 15 Sep 2026 · Prince William County Finance and Budget Committee

The Art of True Happiness | Dr. Arthur Brooks 2h 49m · 14 Sep 2026 · Huberman Lab

The Chris Wolfe Podcast: The Power of Quality Supplements 48 min · 14 Sep 2026 · EyeCode Media

1208: TM Europe win the '26 Solheim Cup 1h 49m · 13 Sep 2026 · No Laying Up - Golf Podcast

MORNING TEA: Harry & Meghan's Brutal SNL Roast, Lady Gaga's Baby News & Dakota Johnson's New Man 8 min · 13 Sep 2026 · The Spill

"I don't think they have enough match winners."| First Thoughts - Brisbane vs Adelaide (14.09.26) 15 min · 13 Sep 2026 · SEN Breakfast

Report any issue

Source

Recorded11 Jun 2021

Publisherbehaviourspeak.com ↗

Handlerec:2013438

Show notes

In episode 13 Ben chats with Dr. Alison Cox, BCBA-D, about her research on psychotropic medication including effects on behavioural function, side effects and more! Continuing Education Units (CEUs): https://cbiconsultants.com/shop BACB: 1.5 Learning IBAO: 1.5 Learning QABA: 1.5 General Show Notes: Brock University: https://brocku.ca/social-sciences/applied-disability-studies/people-in-the-department/alison-cox Dr. Marc Lanovaz - The Behaviour Speak Podcast Episode: https://www.behaviourspeak.com/e/episode-8-artificial-intelligence-and-behaviour-analysis-with-marc-lanovaz-phd-bcba-d Tom Freeman Course at FIT: https://abafit.coursewebs.com/cart/pageCourseInfo.aspx?Course_ID=BEHP1054&Section_ID=0&add_to_cart=0 References: Cox, A., Leung, J., Morgan, M-C & Anderson, B. (2021). Examining research trends in the treatment of adults with problem behavior and intellectual and developmental disabilities: A brief review. Behavioral Development, 26(1), 14-28. Cox, A. D. & Virues‐Ortega, J. (2016). Interactions between behavior function and psychotropic medication. Journal of Applied Behavior Analysis, 49, 85-104. https://doi.org/10.1002/jaba.247 Crosland, K. A., Zarcone, J. R., Lindauer, S. E., Valdovinos, M. G., Zarcone, T. J., Hellings, J. A., & Schroeder, S. R. (2003). Use of functional analysis methodology in the evaluation of medication effects. Journal of Autism and Developmental Disorders, 33(3), 271-279. https://doi.org/10.1023/a:1024402500425 Fisher, W., Piazza, C. C., Page, T. J. (1989). Assessing independent and interactive effects of behavioral and pharmacologic interventions for a client with dual diagnoses. Journal of Behavior Therapy and Experimental Psychiatry, 20(3), 241-250. https://doi.org/10.1016/0005-7916(89)90029-3 Northup, J., Fusilier, I., Swanson, V., Huete, J., Bruce, T., Freeland, J., Gulley, V. & Edwards, S. (1999). Further analysis of the separate and interactive effects of methylphenidate and common classroom contingencies. Journal of Applied Behavior Analysis, 32, 35-50. https://doi.org/10.1901/jaba.1999.32-35 Northup, J., Fusilier, I., Swanson, V., Roane, H. & Borrero, J. (1997). An evaluation of methylphenidate as a potential establishing operation for some common classroom reinforcers. Journal of Applied Behavior Analysis, 30, 615-625. https://doi.org/10.1901/jaba.1997.30-615 Rapp, J. T., Swanson, G., Dornbusch, K. (2007). Temporary increases in problem behavior and sleep disruption following decreases in medication: A descriptive analysis of conditional rates. Behavior Modification, 31, 825-846. https://doi.org/10.1177/0145445507301653 Valdovinos, M. G. (2019). Psychotropic medication in intellectual and developmental disabilities: Patterns of use and recommendations for monitoring effects. Current Developmental Disorders Reports, 6, 195–201. https://doi.org/10.1007/s40474-019-00179-5 Valdovinos, M. G., Caruso, M., Roberts, C., Kim, G., Kennedy, C. H., Bodfish, J. (2005). Medical and behavioral symptoms as potential medication side effects in adults with developmental disabilities. American Journal of Mental Retardation, 110(3), 164-170. https://doi.org/10.1352/0895-8017(2005)110<164:MABSAP>2.0.CO;2 Valdovinos, M. G., Schieber, E., McMahon, M. et al. (2017). Adverse side effects of psychotropic medication and challenging behavior: Pilot work assessing impact. Journal of Developmental and Physical Disabilities, 29, 969-982. https://doi.org/10.1007/s10882-017-9570-0 van Haaren, F. & Weeden, M. (2013). Some guidelines for conducting research in applied behavioral pharmacology. Journal of Applied Behavior Analysis, 46, 498-506. https://doi.org/10.1002/jaba.47 Zarcone, J. R., Lindauer, S. E., Morse, P. S., Crosland, K. A., Valdovinos, M. G., McKerchar, T. L., Matthew Reese, R., Hellings, J. A., & Schroeder, S. R. (2004). Effects of risperidone on destructive behavior of persons with developmental disabilities: III. Functional analysis. American Journal on Mental Retardation, 109(4), 310-321. https://doi.org/10.1352/0895-8017(2004)109<310:EORODB>2.0.CO;2

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related